Peptide-DC Vaccine Boosting pMHC-directed CAR-T Cell Solutions

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

pMHC-directed CAR-T cells are a promising approach in cancer immunotherapy designed to target specific intracellular proteins that are presented by MHC molecules on the surface of cancer cells. Peptide-dendritic cell (DC)-based vaccines may help activate and enhance the function of CAR-T cells, potentially overcoming antigen heterogeneity and tumor escape mechanisms. Therefore, the combination of pMHC-directed CAR-T cells with a peptide-DC vaccine holds great potential for improving the efficacy and specificity of cancer immunotherapy, offering a potential synergistic effect in targeting and eliminating cancer cells. Additionally, the combination therapy may improve the persistence and effectiveness of CAR-T cells within the tumor microenvironment. At Creative Biolabs, we specialize in designing and optimizing tailored peptide-DC vaccine solutions to enhance the efficiency of pMHC-directed CAR-T cell therapy.

Fig.1 pMHC-directed CAR-T cells are boosted by DC vaccination.¹

Services

Our team of experts has extensive experience in the design and production of CAR-T cells, as well as in the development of peptide-DC vaccines. We provide one-stop solutions for the combination of the peptide-DC vaccine and pMHC-directed CAR-T cell therapy. We utilize state-of-the-art technology and innovative methods to analyze the activity of pMHC-directed CAR-T cells both in vitro and in vivo, including their ability to recognize and kill cancer cells, their proliferative capacity, and their cytokine production profile.

Generation of CAR-T Cells

Creative Biolabs also offers a comprehensive range of pMHC-directed CAR-T cell development services, from the initial identification of the target peptide-MHC complex to the generation of a highly potent CAR-T cell product. Our services are tailored to meet the unique requirements of each client's research project.

Generation of Peptide-DC Vaccine

We also offer peptide-DC vaccine development and characterization services, including peptide synthesis, loading of peptides onto DCs, and maturation of DCs. Our peptide-DC vaccines are designed to stimulate the immune system by presenting tumor-specific peptides in complex with MHC molecules to T cells. By combining these vaccines with pMHC-directed CAR-T cells, we aim to enhance anti-tumor immune responses and improve therapeutic outcomes.

In Vitro Functional Analysis

Our in vitro CAR-T cell functional analysis services include assays to measure CAR-T cell proliferation, cytotoxicity, and cytokine production upon stimulation with the peptide-DC vaccine.

In Vivo Functional Analysis

Our in vivo functional analysis service includes a comprehensive evaluation of pMHC-directed CAR-T cell activity in a mouse tumor model. We utilize state-of-the-art imaging techniques and immunological assays to assess tumor regression, CAR-T cell trafficking, and anti-tumor immune responses.

Highlights & Advantages

Fully custom services to ensure that the most appropriate combination solution of CAR-T and vaccine
One-stop solutions from CAR-T development, vaccine development, to in vitro and in vivo functional analysis
State-of-the-art technology and methods to ensure consistency and efficiency throughout the process.
Saves time and effort while maintaining the highest standards of quality

Contact Us

Our team's expertise in CAR-T cell design and production, coupled with our knowledge of peptide-DC vaccine development, ensures that our solutions are both effective and safe. By providing one-stop solutions for the combination of these two therapies, we aim to simplify the process for our clients, saving them time and effort. If you are interested in exploring the potential of DC vaccines to boost your CAR-T cell therapy, please contact us today.

Reference

Akahori, Yasushi, et al. "Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination." Blood, The Journal of the American Society of Hematology 132.11 (2018): 1134-1145.